Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | CNR2 | P34972 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.51 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11578842 | 0.95 | KMT2A (0.69) | KMT2AMEN1SMN1; SMN2PTK2KDM4E | |
| SCHEMBL13789666 | 0.81 | KMT2A (0.63) | KMT2AMEN1SMN1; SMN2PTK2KDM4E | |
| SCHEMBL4066836 | 0.80 | KMT2A (0.67) | KMT2AMEN1SMN1; SMN2PTK2KDM4E | |
| SCHEMBL11638233 | 0.79 | PTK2 (0.59) | KMT2AMEN1SMN1; SMN2PTK2KDM4E | |
| SCHEMBL10202041 | 0.79 | PTK2 (0.73) | KMT2AMEN1SMN1; SMN2PTK2KDM4E | |
| SCHEMBL17010936 | 0.78 | PTGS1 (0.53) | KMT2AMEN1SMN1; SMN2KDM4EPOLB | |
| SCHEMBL16838134 | 0.78 | KMT2A (0.63) | KMT2AMEN1SMN1; SMN2KDM4EPOLB | |
| SCHEMBL1704195 | 0.78 | PTK2 (0.71) | KMT2AMEN1SMN1; SMN2PTK2KDM4E | |
| SCHEMBL7930548 | 0.77 | KMT2A (0.63) | KMT2AMEN1SMN1; SMN2KDM4EPOLB | |
| SCHEMBL3702839 | 0.77 | KMT2A (0.68) | KMT2AMEN1SMN1; SMN2KDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1915150-B1 | USE OF THIENOPYRIDONE DERIVATIVES AS AMPK ACTIVATORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | MERCK PATENT GMBH (DE) | 2011-01-26 | — | — | EP | disclosed |
| US-20090105293-A1 | USE OF THIENOPYRIDONE DERIVATIVES AS AMPK ACTIVATORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | MERCK PATENT GESELLSCHAFT (DE) | 2009-04-23 | — | — | US | disclosed |
| EP-1915150-A1 | USE OF THIENOPYRIDONE DERIVATIVES AS AMPK ACTIVATORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Merck Patent GmbH (DE) | 2008-04-30 | — | — | EP | disclosed |
| WO-2007019914-A1 | USE OF THIENOPYRIDONE DERIVATIVES AS AMPK ACTIVATORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | MERCK PATENT GMBH (DE) | 2007-02-22 | — | — | WO | disclosed |
| EP-1754483-A1 | Use of thienopyridone derivatives as AMPK activators and pharmaceutical compositions containing them | Merck Sante (FR) | 2007-02-21 | — | — | EP | disclosed |
| US-5602144-A | ADMINISTERING FOR TREATMENT OF CEREBRAL ISCHAEMIA OR SCHIZOPHRENIA | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1997-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105293-A1 | USE OF THIENOPYRIDONE DERIVATIVES AS AMPK ACTIVATORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PRKAR2A, PRKAR2B, PRKAB1 | KMT2A 2788/4885MEN1 3861/4885SMN1; SMN2 4293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.